Skip to main content
NCBI home page
Frontiers in Molecular Biosciences logoLink to Frontiers in Molecular Biosciences
. 2025 Feb 13;12:1509803. doi: 10.3389/fmolb.2025.1509803

Long-term iron supplementation in four patients with X-linked erythropoietic protoporphyria: associations with serum proteins and erythrocyte protoporphyrin levels—a single-centre retrospective study

Anna-Elisabeth Minder 1,2, Francesca Granata 3, Franziska van Breemen 2,4, Xiaoye Schneider-Yin 2,4, Elisabeth I Minder 1,2, Lanja Saleh 2,4,†,#, Jasmin Barman-Aksözen 2,4,5,6,*,†,#
PMCID: PMC11864907  PMID: 40017630

Abstract

Introduction

X-linked erythropoietic protoporphyria (XLEPP) is an ultra-rare inborn error of the heme biosynthesis characterised by the accumulation of large amounts of protoporphyrin IX (PPIX) and zinc-protoporphyrin in the erythrocytes. PPIX absorbs the energy of the visible light range and upon exposure causes painful phototoxic reactions and tissue damage. In addition, PPIX is excreted via the liver and bile, and can induce liver failure that requires life-saving liver transplantation. Case reports and data from a limited number of patients enrolled in a prospective study indicate that supplementation with iron, a co-substrate of the heme biosynthesis, can decrease blood PPIX concentrations and improve liver damage and photosensitivity in patients with XLEPP. However, long-term data on safety and effectiveness of iron supplementation in XLEPP to support this treatment strategy is limited.

Methode

Here, we report the experience and long-term effects over up to 8 years of iron supplementation of the four patients with XLEPP in the Swiss cohort.

Results

Our study shows that iron supplementation was safe and effective in lowering blood PPIX concentrations in our patients in the long term.

Discussion

However, monitoring for adequate dosing and long-term effects is advisable and a standardisation of treatment protocols and international best practice guidelines are needed.

Keywords: erythropoietic protoporphyria, X-linked erythropoietic protoporphyria, iron, safety, effectiveness, treatment, ALAS2

1 Introduction

Iron is essential for life, yet it is a highly reactive and potentially toxic substance. Therefore, its absorption, utilisation and distribution in the body is strictly regulated (Abbaspour et al., 2014; Yuen and Becker, 2023; Belot et al., 2024). One of the major demands for iron in the body is created by the erythropoietic heme biosynthesis to produce hemoglobin (Belot et al., 2024). Heme synthesis occurs in eight consecutive steps: The substrates glycine and succinyl-CoA are initially converted to delta-aminolevulinic acid (ALA) and further processed into the monopyrrol porphobilinogen, which serves as the building block for the porphyrin ring (Figure 1). In the final step, ferrochelatase (FECH) incorporates ferrous iron into the last precursor, protoporphyrin IX (PPIX), to form heme. In case of iron deficiency, FECH uses its alternative substrate, zinc (Zn), to form zinc-protoporphyrin (ZnPP), which, however, cannot replace heme.

FIGURE 1.

FIGURE 1

Open in a new tab

The erythroid heme biosynthesis pathway.

Iron not only serves as a substrate, but also forms an essential part of the indispensable iron-sulfur clusters in the eukaryotic FECH and aminolevulinic acid dehydratase (ALAD) enzymes in the heme biosynthetic pathway (Dailey et al., 2000; Belot et al., 2024). In addition, in-vitro studies suggest that iron deprivation can lead to decreased FECH enzyme stability and an increase in aberrant splicing of FECH mRNA (Taketani et al., 2000; Crooks et al., 2010; Barman-Aksözen et al., 2013). Most importantly, iron regulates the synthesis rate of porphyrins: Delta-aminolevulinate synthase 2 (ALAS2) acts as the rate-limiting enzyme in the erythroid heme biosynthesis (Bhasker et al., 1993; Melefors et al., 1993; Sadlon et al., 1999; Peoc’h et al., 2019). The 5′-untranslated region of ALAS2 mRNA contains a conserved stem look structure known as the iron-responsive element (IRE), which serves as the binding site for the IRE-binding proteins (IRPs) 1 and 2. A low intracellular iron concentration promotes the binding of IRP to the IRE which prevents translation of the mRNA into ALAS2 enzyme and therefore the synthesis of ALA. The IRP-IRE mechanism establishes a direct link between iron availability and the capacity of the erythropoietic heme biosynthetic pathway, ensuring efficient iron utilisation while preventing the accumulation of toxic heme precursors during iron deficiency. Apparently, this fine-tuned balance is disturbed by pathogenic variants in the genes for FECH and ALAS2 which both lead to the accumulation of PPIX and disturbances in the iron metabolism (Poli et al., 2021; Poli et al., 2024).

As first described by Magnus et al. (1961) and further elucidated by Went and Klasen (1984) and Gouya et al. (2002), a partial deficiency in FECH causes EPP1 (OMIM # 177000), which is characterised by the accumulation of large amounts of PPIX in the erythrocytes. PPIX absorbs the energy of the visible light range and upon exposure causes painful phototoxic reactions and tissue damage (Maitra et al., 2019). In addition, PPIX is excreted via the liver and bile, and in 2%–5% of the patients induces liver failure that requires life-saving liver transplantation (Anstey and Hift, 2007; Wahlin et al., 2011a; Wensink et al., 2022). EPP1 is also associated with disturbances in the iron metabolism: while a pronounced anaemia is only present in a minority of the patients, low serum iron, ferritin and transferrin saturation and hypochromic, microcytic erythrocytes are commonly observed and indicate an iron deficiency (Holme et al., 2007; Delaby et al., 2009; Wahlin et al., 2011b; Balwani et al., 2017; Minder et al., 2021). However, iron supplementation, despite moderately increasing blood hemoglobin concentrations, has been shown to increase erythrocyte PPIX concentrations and phototoxicity in most of the investigated patients with a confirmed EPP1 (Balwani et al., 2022; Heersfordt et al., 2024). The observed increase in PPIX under iron supplementation may be linked to elevated expression of ALAS2 mRNA and protein, as measured in peripheral blood samples of patients with EPP1: under iron supplementation, the translational repression of the ALAS2 mRNA is lifted which in turn leads to an increase in ALA synthesis and enhanced PPIX accumulation (Barman-Aksözen et al., 2015; Granata et al., 2022). Interestingly, the exact cause for the iron deficiency in EPP1 patients remains unclear: On the one hand, hepcidin, a hepatic peptide hormone that regulates iron homeostasis and prevents iron uptake und release from the body iron stores during inflammation is not upregulated and therefore does not prevent nutritional iron absorption in EPP1 (Bossi et al., 2015; Barman-Aksozen et al., 2017; Graziadei et al., 2022). On the other hand, in patients with EPP1, no indication for either excessive iron storage or iron loss has been observed so far.

In 2008, Whatley et al. identified gain of function mutations in ALAS2 exon 11 in a subgroup of patients who were negative for FECH-mutations. This discovery led to the characterised of X-linked EPP (XLEPP, OMIM # 300752), which is clinically indistinguishable from EPP1 but is characterised by the additional accumulation of zinc-protoporphyrin (ZnPP) in the erythrocytes. In XLEPP, the overly active ALAS2 enzyme is no longer regulated by iron availability but leads to the overproduction of ALA in maturing erythrocytes which is converted to PPIX (Ducamp et al., 2013; Fratz et al., 2015). It is assumed that iron becomes the limiting factor of the heme biosynthesis in XLEPP and that FECH (which is not affected in XLEPP) utilises its alternative substrate zinc in addition to iron. Case reports and data from three patients enrolled in a prospective study indicate that iron supplementation may decrease blood PPIX concentrations and improve liver damage and photosensitivity in patients with XLEPP (Table 1). More recently, Yien et al. (2017) in one family discovered that mutations in the CLPX gene can cause EPP2 (OMIM # 618015). CLPX regulates the expression of ALAS2 and EPP2 resembles the clinical picture of XLEPP.

TABLE 1.

Previously reported cases of confirmed XLEPP treated with iron supplementation.

References n Patient characteristics Treatment PPIX baseline PPIX under treatment Clinical effect Follow-up period
Whatley et al. (2008) 1 n.a. Oral iron Ca.170 μmol/L
ZnPP: ca. 30 μmol/L		 Ca. 50 μmol/L
ZnPP: ca. 30 μmol/L		 - Increase in Hb and serum ferritin 30 months
Sonderup et al. (2009) 2 Male, age 63 Iron i.v. n.a. Initial transient increase, followed by a decrease compared to baseline - Normalisation of liver function tests within 7 days of therapy.
-Reduction in photosensitivity		 3 months
Female, age 24 Iron i.v. n.a. Initial transient increase, followed by a decrease compared to baseline - Normalisation of liver function tests within 7 days of therapy.
- Reduction in photosensitivity		 3 months
Landefeld et al. (2016) 1 Male, age 9, Caucasian Treatment because of liver decompensation: 12 unites red blood cells (=1800 mg iron) over 2 months
−400 mg haem arginate i.v. (=103 mg iron)		 94.6 μmol/L, (normal <0.09) 2 μmol/L - Reversal of liver failure requiring additional 17 RBC transfusions (=2,550 mg iron) and iron chelation therapy
- Oral iron as maintenance therapy for 3 years: Normalised liver function test and improved liver biopsy findings, reduction in phototoxicity		 3 years
Balwani et al. (2022) 3 Female, Caucasian 325 ferrous sulfate orally twice daily (=130 mg elemental iron per day), 3 months n.a. Decrease compared to baseline n.a. 3 months (early study termination, no follow-up reported after 3 months)
Female, Caucasian 325 ferrous sulfate orally twice daily (=130 mg elemental iron per day), 12 months 1,705 μg/dL 560 μg/dL - Reduction in phototoxicity
- No adverse events		 12 months
Female, Caucasian 325 ferrous sulfate orally twice daily (=130 mg elemental iron per day), 12 months 2,440 μg/dL 1,218 μg/dL - Reduction in phototoxicity 12 months
Open in a new tab

Studies across different cohorts have shown that 2%–10% of patients affected by PPIX accumulation carry gain of function mutations in ALAS2, and that XLEPP is associated with higher blood PPIX concentrations and an increased risk for liver failure as compared to EPP1 (Whatley et al., 2008; Ducamp et al., 2013; Brancaleoni et al., 2016; Balwani et al., 2017; Ventura et al., 2020). Several porphyria treatment centres currently recommend their patients with XLEPP to supplement iron, with anecdotally good results (Di Pierro et al., 2022; Leaf and Dickey, 2023). However, long-term data on safety and effectiveness of iron supplementation in XLEPP to support this advice is still limited. Here, we report the experience and long-term effects of iron supplementation of four patients with XLEPP in the Swiss cohort. For our study, we retrospectively analysed the available laboratory results from the clinical records with the aim to assess long-term safety and effectiveness of iron supplementation in XLEPP and to identify potential markers for the monitoring of the treatment effects.

2 Material and methods

2.1 Informed consent

Prior to the analysis, all patients signed written informed consent forms for the participation in the porphyria biobank project, which was approved by the Cantonal Ethics Committee in Zurich (BASEC 2018-00758). In addition, a separate written informed consent was obtained from all patients prior to mutational analysis of FECH and ALAS2 genes. All investigations were conducted in accordance with the ethical principles of the Declaration of Helsinki.

2.2 Treatment protocol

After the identification of XLEPP in 2008, all patients with negative FECH mutational analysis and/or elevated erythrocyte ZnPP concentrations in the Swiss cohort were reanalysed. From 2016 on, based on beneficial effects reported in the literature, the four XLEPP patients identified in the Swiss cohort were advised to take iron supplements. In case oral iron supplements were not tolerated or efficient, iron infusions were offered. The frequency and dosing were adjusted to the individual patients need after assessing their PPIX, ZnPP, ferritin and hemoglobin concentrations. We usually recommend additional iron supplementation on an individual basis when ZnPP increases to >30% of total PPIX and/or >50% of metal free PPIX and/or in case the liver function tests are increased and/or hemoglobin decreased or ferritin decreased below 50 ug/L, taking the patients wellbeing into account. After establishing a suitable dosing regime and because of the apparent well tolerability of the treatment and to reduce the burden to having to travel to the national reference centre for each appointment, iron supplementation was organised and performed locally with the patient`s GPs. During their routine visits at our treatment centre, parameters for iron and porphyrin metabolism, liver health and haematological parameters are monitored every 6 months. All four patients with XLEPP are in addition treated with afamelanotide for the prevention of phototoxic reactions.

2.3 Analyses

All biochemical analyses were performed at the Institute of Laboratory Medicine (ILM) at the Municipal Hospital Zurich as routine analyses. Quantification of erythrocyte porphyrins and DNA sequencing were performed as published earlier (Minder and Schneider-Yin, 2008). Results for ferritin (which is also an acute phase protein) were excluded from the analysis in the case of an elevated c-reactive protein. The ILM is part of the Swiss Reference Centre for Porphyrias and all routine analyses, including the porphyria and genetic analyses, are accredited by the Swiss Accreditation Service (SAS), according to the ISO norm 15,189 for medical laboratories.

2.4 Statistical analysis

For correlations, Kendall`s Tau rank correlation test was performed. A correlation coefficient r of 0.4–0.69 was considered as moderate, 0.7–0.89 as strong, and ≥0.9 as a very strong correlation. Data with independent samples were analysed by Mann-Whitney U test (R Core Team, 2021). A two-sided p ≤ 0.05 was considered statistically significant.

3 Results

3.1 Patients included in the study

We included n = 4 patients from two families in our study, all having a biochemically and/or genetically confirmed diagnosis of XLEPP (Figure 2; Table 2).

FIGURE 2.

FIGURE 2

Open in a new tab

Pedigrees of the two families with XLEPP in the Swiss cohort.

TABLE 2.

Patient characteristics, baseline laboratory values and time to follow-up since recommendation of iron supplementation.

Age, and sex Diagnosis PPIX (μmol/L) and ZnPP (μmol/L) Hb (g/dL) and ferritin (μg/L) Follow-up period since iron supplementation and form of administration
XLEPP 1 49, female Biochemical and mutational analysis. FECH: negative
ALAS2: c.1706–1709delAGTG (p.E569GfsX24)		 22 (<0.2)
13.9 (<1.3)		 13 (12–15.4)
24 (10–160)		 8 years oral iron
XLEPP 2 61, female Biochemical and mutational analysis. FECH: negative ALAS2: c.1706–1709delAGTG; (p.E569GfsX24) 20.5 (<0.2)
4.36 (<1.3)		 11.5 (12–15.4)
41 (10–160)		 8 years
Iron i.v.
XLEPP 3 34, male Biochemical 30.9 (<0.2)
8.6 (<1.3)		 14.4 (13.5–17.2)
63 (30–400)		 5 years unknown
XLEPP 4 31, male Biochemical 48.6 (<0.2)
11.2 (<1.3)		 12.9 (13.5–17.2)
10 (30–400)		 8 years
Iron i.v.
Open in a new tab

In bold: pathological parameters.

3.2 Safety and effectiveness of iron substitution

The effect of iron substitution was assessed by analysis of the protoporphyrin, hemoglobin and serum ferritin concentrations. In addition, platelet count was analysed (Table 3). Mean and median values of all laboratory parameters can be found in the supplement (Supplementary Tables S1A–D).

TABLE 3.

Mean change before vs under iron supplementation.

Mean change [%] PPIX ZnPP Hb Ferritin Platelets
XLEPP 1 −42.6* −46.7* +2.4 +209.8 +11.6
XLEPP 2 −4.5 +1.7 +6.8* +113.7 +35.8*
XLEPP 3 −44.3 −5.6 +1.4 +214.7 +41
XLEPP 4 −64.5* −36.1* +15.4* +978.8 +94.3*
Open in a new tab

*indicates p ≤ 0.05; ** indicates p < 0.001; *** indicates p < 0.0001; in bold: parameters which were pathological at baseline and remain pathological; underlined: normalisation of previously pathological parameters.

In all four patients with XLEPP in the Swiss cohort, iron supplementation was accompanied by decreased erythrocyte PPIX concentrations, although only reaching a statistically significant difference in two of the patients (Figure 3A). In addition, a decrease in erythrocyte ZnPP concentrations was observed in 3 of the four patients (Table 3; Figure 3B). Concomitantly, hemoglobin, serum ferritin and platelet count increased, and lead to a normalisation of previously pathological values (Figures 3C–E). Iron stores as assessed by serum ferritin concentrations increased in all patients but remained within the reference ranges with no indication for iron overload. In addition, bilirubin remained within the normal range in all four patients (Supplementary Tables S1A–D). Moreover, in patient 1, pathological liver enzymes normalised under treatment with iron supplementation.

FIGURE 3.

FIGURE 3

Open in a new tab

(A) Erythrocyte PPIX concentrations. (B) Erythrocyte ZnPP concentrations. (C) Blood hemoglobin concentrations. (D) Serum ferritin concentrations. (E) Platelet count.

3.3 Markers for treatment monitoring

We further assessed which parameters could be used to monitor treatment effects and support dosing decisions (Table 4). In our cohort, platelet counts in three of the four patients inversely and statistically significantly correlated with erythrocyte PPIX concentrations. Moreover, in all four patients, a trend was observed that erythrocyte PPIX concentrations positively correlate with ZnPP and negatively correlate with hemoglobin and ferritin.

TABLE 4.

Correlations PPIX.

PPIX vs ZnPP (n) Hb (n) Ferritin (n) Platelets (n)
XLEPP 1 0.3* (32) −0.01 (31) −0.6** (15) −0.5*** (31)
XLEPP 2 0.1 (25) −0.4* (23) −0.1 (19) −0.3* (23)
XLEPP 3 0.3 (11) −0.3 (10) −0.4 (9) −0.4 (9)
XLEPP 4 0.4* (22) −0.6*** (21) −0.5* (17) −0.5** (21)
Open in a new tab

*indicates p ≤ 0.05; ** indicates p < 0.001; *** indicates p < 0.0001.

4 Discussion

In all four of our patients with XLEPP, the recommendation to start iron supplementation resulted in a decrease in mean erythrocyte PPIX concentrations, ranging from 4.5% to 64.5%, as compared to the mean erythrocyte PPIX concentrations before iron supplementation was recommended. Moreover, in all but one patient erythrocyte ZnPP concentrations decreased, too. Interestingly, the mean decrease in erythrocyte PPIX concentrations was more pronounced than the decrease in ZnPP which indicates that limited substrate availability, i.e., an iron deficiency, contributes to the PPIX accumulation in XLEPP. Concomitantly, serum ferritin and blood hemoglobin concentrations increased, but remained within their respective reference ranges without signs for an iron overload throughout the observational period between five to 8 years. Clinically, the patients reported an improvement of their general wellbeing with iron supplementation. In none of the patients a complete freedom from phototoxic reactions was achieved by iron supplementation, which is in accordance with the clinical experience in our treatment centre that erythrocyte PPIX concentration ≥5 μmol/L cause phototoxic reactions.

Importantly, no direct adverse events or other long-term negative effects of iron supplementation were identified in our cohort. However, elevation in liver enzymes in two of the patients warrant further monitoring. Based on the current understanding of the XLEPP disease pathophysiology, decreased blood PPIX concentrations should lower the risk for liver involvement. As currently most experience with iron supplementation is based on short-term treatment of iron deficiency and no active mechanism to excrete iron from the human body is known, the question remains on where the cumulative iron doses end up (Fischer and Naughton, 2004;Fernández-Gaxiola and De-Regil, 2019).

An incidental finding of our study was that two of the patients at baseline showed mild thrombocytopenia (low platelet count), which was resolved under iron treatment. While the interplay between iron and platelet count is not yet completely understood, low platelet count has been described in patients with an absolute iron deficiency (Brissot et al., 2021). However, the exact mechanism and underlying reasons for the low platelet count observed in our patients with XLEPP needs to be further elucidated.

4.1 Limitations of the study

One of the main limitations of our study is that the iron supplementation was implemented by the local physicians. Also, patients have access to over-the-counter iron supplements. Therefore, we were not able to determine the exact dose and frequency of iron supplementation the patients were using. Moreover, some patients with XLEPP may have started to use iron to better control their phototoxicity even before the condition had been first described. Especially women in child-bearing age likely have been using iron in order to treat iron deficiency due to menstrual blood loss. Out of the reasons discussed above, our analysis might not reflect the full extent of the effect iron supplementation has on blood PPIX concentrations in XLEPP. However, the correct diagnosis allowed to monitor these patients and adjust the iron doses to their individual needs which might be the reason on why we in all four patients nevertheless observed a decrease in mean PPIX blood concentrations. Prospective study protocols and systematic monitoring of iron intake are required for a definitive assessment.

5 Conclusion

Based on our own data and the published and informally shared experiences of the porphyria treatment centres internationally iron supplementation seems to be safe and effective in lowering blood PPIX concentrations in patients with XLEPP also in the long term. However, monitoring for adequate dosing and long-term effects is advisable. Moreover, a standardisation of treatment protocols and long-term experiences is needed. As XLEPP is a subforum of an already ultra-rare disease, data from the single treatment centres should be shared to enable formulation of best practice guidelines.

Funding Statement

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The work was supported by the Stiftung Stadtspital Zürich.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by Kantonale Ethikkommission Zürich. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

A-EM: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Writing–original draft, Writing–review and editing. FG: Conceptualization, Investigation, Methodology, Validation, Visualization, Writing–review and editing. FB: Data curation, Project administration, Resources, Software, Writing–review and editing. XS-Y: Data curation, Project administration, Resources, Supervision, Writing–review and editing. EM: Conceptualization, Investigation, Methodology, Supervision, Writing–review and editing. LS: Funding acquisition, Methodology, Project administration, Resources, Software, Writing–review and editing. JB-A: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing–original draft.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2025.1509803/full#supplementary-material

DataSheet1.PDF (203.2KB, PDF)

References

  1. Abbaspour N., Hurrell R., Kelishadi R. (2014). Review on iron and its importance for human health. J. Res. Med. Sci. official J. Isfahan Univ. Med. Sci. 19 (2), 164–174. [PMC free article] [PubMed] [Google Scholar]
  2. Anstey A. V., Hift R. J. (2007). Liver disease in erythropoietic protoporphyria: insights and implications for management. Postgrad. Med. J. 83 (986), 739–748. 10.1136/gut.2006.097576 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Balwani M., Naik H., Anderson K. E., Bissell D. M., Bloomer J., Bonkovsky H. L., et al. (2017). Clinical, biochemical, and genetic characterization of north American patients with erythropoietic protoporphyria and X-linked protoporphyria. JAMA dermatol. 153 (8), 789–796. 10.1001/jamadermatol.2017.1557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Balwani M., Naik H., Overbey J. R., Bonkovsky H. L., Bissell D. M., Wang B., et al. (2022). A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria. Mol. Genet. metabolism Rep. 33, 100939. 10.1016/j.ymgmr.2022.100939 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barman-Aksoezen J., Girelli D., Aurizi C., Schneider-Yin X., Campostrini N., Barbieri L., et al. (2017). Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity. J. Inherit. metabolic Dis. 40 (3), 433–441. 10.1007/s10545-017-0017-7 [DOI] [PubMed] [Google Scholar]
  6. Barman-Aksözen J., Béguin C., Dogar A. M., Schneider-Yin X., Minder E. I. (2013). Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF(65.). Blood cells, Mol. and Dis. 51 (3), 151–161. 10.1016/j.bcmd.2013.05.008 [DOI] [PubMed] [Google Scholar]
  7. Barman-Aksözen J., Minder E. I., Schubiger C., Biolcati G., Schneider-Yin X. (2015). In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability. Blood cells, Mol. and Dis. 54 (1), 71–77. 10.1016/j.bcmd.2014.07.017 [DOI] [PubMed] [Google Scholar]
  8. Belot A., Puy H., Hamza I., Bonkovsky H. L. (2024). Update on heme biosynthesis, tissue-specific regulation, heme transport, relation to iron metabolism and cellular energy. Liver Int. 44, 2235–2250. 10.1111/liv.15965 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bhasker C. R., Burgiel G., Neupert B., Emery-Goodman A., Kühn L. C., May B. K. (1993). The putative iron-responsive element in the human erythroid 5-aminolevulinate synthase mRNA mediates translational control. J. Biol. Chem. 268 (17), 12699–12705. 10.1016/S0021-9258(18)31444-3 [DOI] [PubMed] [Google Scholar]
  10. Bossi K., Lee J., Schmeltzer P., Holburton E., Groseclose G., Besur S., et al. (2015). Homeostasis of iron and hepcidin in erythropoietic protoporphyria. Eur. J. Clin. Investig. 45, 1032–1041. 10.1111/eci.12503 [DOI] [PubMed] [Google Scholar]
  11. Brancaleoni V., Balwani M., Granata F., Graziadei G., Missineo P., Fiorentino V., et al. (2016). X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria. Clin. Genet. 89 (1), 20–26. 10.1111/cge.12562 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Brissot E., Troadec M. B., Loréal O., Brissot P. (2021). Iron and platelets: a subtle, under-recognized relationship. Am. J. Hematol. 96 (8), 1008–1016. 10.1002/ajh.26189 [DOI] [PubMed] [Google Scholar]
  13. Crooks D. R., Ghosh M. C., Haller R. G., Tong W. H., Rouault T. A. (2010). Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery. Blood, J. Am. Soc. Hematol. 115 (4), 860–869. 10.1182/blood-2009-09-243105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dailey H., Dailey T., Wu C. K., Medlock K.-F., Rose J. P., Wang B.-C., et al. (2000). Ferrochelatase at the millennium: structures, mechanisms and [2Fe-2S] clusters. CMLS, Cell. Mol. Life Sci. 57, 1909–1926. 10.1007/PL00000672 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Delaby C., Lyoumi S., Ducamp S., Martin-Schmitt C., Gouya L., Deybach J. C., et al. (2009). Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. Cell. Mol. Biol. (Noisy-le-Grand, France) 55 (1), 45–52. [PubMed] [Google Scholar]
  16. Di Pierro E., Granata F., De Canio M., Rossi M., Ricci A., Marcacci M., et al. (2022). Recognized and emerging features of erythropoietic and X-linked protoporphyria. Diagnostics 12 (1), 151. 10.3390/diagnostics12010151 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ducamp S., Schneider-Yin X., de Rooij F., Clayton J., Fratz E. J., Rudd A., et al. (2013). Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP). Hum. Mol. Genet. 22 (7), 1280–1288. 10.1093/hmg/dds531 [DOI] [PubMed] [Google Scholar]
  18. Fernández-Gaxiola A. C., De-Regil L. M. (2019). Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women. Cochrane Cochrane Database Syst. Rev. 1, CD009218. 10.1002/14651858.CD009218.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fisher A. E., Naughton D. P. (2004). Iron supplements: the quick fix with long-term consequences. Nutr. J. 3, 2. 10.1186/1475-2891-3-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Fratz E. J., Clayton J., Hunter G. A., Ducamp S., Breydo L., Uversky V. N., et al. (2015). Human erythroid 5-aminolevulinate synthase mutations associated with X-linked protoporphyria disrupt the conformational equilibrium and enhance product release. Biochemistry 54 (36), 5617–5631. 10.1021/acs.biochem.5b00407 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gouya L., Puy H., Robreau A. M., Bourgeois M., Lamoril J., Da Silva V., et al. (2002). The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat. Genet. 30, 27–28. 10.1038/ng809 [DOI] [PubMed] [Google Scholar]
  22. Granata F., Brancaleoni V., Barman-Aksözen J., Scopetti M., De Luca G., Fustinoni S., et al. (2022). Heme biosynthetic gene expression analysis with dPCR in erythropoietic protoporphyria patients. Front. physiology 13, 886194. 10.3389/fphys.2022.886194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Graziadei G., Duca L., Granata F., De Luca G., De Giovanni A., Brancaleoni V., et al. (2022). Microcytosis in erythropoietic protoporphyria. Front. Physiol. 13, 841050. 10.3389/fphys.2022.841050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Heerfordt I. M., Lerche C. M., Philipsen P. A., Wulf H. C. (2024). Effects of iron supplements in individuals with erythropoietic protoporphyria. Photodiagnosis Photodyn. Ther. 47, 104211. 10.1016/j.pdpdt.2024.104211 [DOI] [PubMed] [Google Scholar]
  25. Holme S. A., Worwood M., Anstey A. V., Elder G. H., Badminton M. N. (2007). Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 110 (12), 4108–4110. 10.1182/blood-2007-04-088120 [DOI] [PubMed] [Google Scholar]
  26. Landefeld C., Kentouche K., Gruhn B., Stauch T., Rößler S., Schuppan D., et al. (2016). X-linked protoporphyria: iron supplementation improves protoporphyrin overload, liver damage and anaemia. Br. J. Haematol. 173 (3), 482–484. 10.1111/bjh.13612 [DOI] [PubMed] [Google Scholar]
  27. Leaf R. K., Dickey A. K. (2023). How I treat erythropoietic protoporphyria and X-linked protoporphyria. Blood 141 (24), 2921–2931. 10.1182/blood.2022018688 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Magnus I. A., Jarrett A., Prankerd T. A., Rimington C. (1961). Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 2 (7200), 448–451. 10.1016/S0140-6736(61)92427-8 [DOI] [PubMed] [Google Scholar]
  29. Maitra D., Bragazzi Cunha J., Elenbaas J. S., Bonkovsky H. L., Shavit J. A., Omary M. B. (2019). Porphyrin-induced protein oxidation and aggregation as a mechanism of porphyria-associated cell injury. Cell Mol. Gastroenterol. Hepatol. 8 (4), 535–548. 10.1016/j.jcmgh.2019.06.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Melefors O., Goossen B., Johansson H. E., Stripecke R., Gray N. K., Hentze M. W. (1993). Translational control of 5-aminolevulinate synthase mRNA by iron-responsive elements in erythroid cells. J. Biol. Chem. 268 (8), 5974–5978. 10.1016/S0021-9258(18)53414-1 [DOI] [PubMed] [Google Scholar]
  31. Minder A. E., Barman-Aksoezen J., Schmid M., Minder E. I., Zulewski H., Minder C. E., et al. (2021). Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study. Ther. Adv. Rare Dis. 2, 26330040211065453. 10.1177/26330040211065453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Minder E., Schneider-Yin X. (2008). “Porphyrins, porphobilinogen, and δ-aminolevulinic acid,” in Laboratory guide to the methods in biochemical genetics. Editors Blau N., Duran M., Gibson K. (Berlin/Heidelberg, Germany: Springer; ). [Google Scholar]
  33. Peoc'h K., Nicolas G., Schmitt C., Mirmiran A., Daher R., Lefebvre T., et al. (2019). Regulation and tissue-specific expression of δ-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias. Mol. Genet. Metabolism 128 (3), 190–197. 10.1016/j.ymgme.2019.01.015 [DOI] [PubMed] [Google Scholar]
  34. Poli A., Schmitt C., Moulouel B., Mirmiran A., Puy H., Lefèbvre T., et al. (2021). Iron, heme synthesis and erythropoietic porphyrias: a complex interplay. Metabolites 11 (12), 798. 10.3390/metabo11120798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Poli A., Schmitt C., Puy H., Talbi N., Lefebvre T., Gouya L. (2024). Erythropoietic protoporphyrias: updates and advances. Trends Mol. Med. 30, 863–874. 10.1016/j.molmed.2024.05.006 [DOI] [PubMed] [Google Scholar]
  36. R Core Team (2021). R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: https://www.R-project.org/(Accessed October 10, 2024). [Google Scholar]
  37. Sadlon T. J., Dell’Oso T., Surinya K. H., May B. K. (1999). Regulation of erythroid 5-aminolevulinate synthase expression during erythropoiesis. Int. J. Biochem. and cell Biol. 31 (10), 1153–1167. 10.1016/S1357-2725(99)00073-4 [DOI] [PubMed] [Google Scholar]
  38. Sonderup M., Corrigall A., Davidson B., Haumann C., Meissner P. (2009). Intravenous iron therapy in two patients with X-linked dominant protoporphyria. Abstr. ASSA-SAGES 2009 Congr. Cape Town. Available at: http://www.samj.org.za/index.php/samj/article/view/3718/2459 (Accessed October 7, 2024). [Google Scholar]
  39. Taketani S., Yasushi A., Yoshitsugu N. (2000). Regulation of the expression of human ferrochelatase by intracellular iron levels. Eur. J. Biochem. 267 (15), 4685–4692. 10.1046/j.1432-1327.2000.01519.x [DOI] [PubMed] [Google Scholar]
  40. Ventura P., Brancaleoni V., Di Pierro E., Graziadei G., Macrì A., Carmine Guida C., et al. (2020). Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy. Eur. J. Dermatol 30 (5), 532–540. 10.1684/ejd.2020.3880 [DOI] [PubMed] [Google Scholar]
  41. Wahlin S., Floderus Y., Stål P., Harper P. (2011b). Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J. Intern. Med. 269 (3), 278–288. 10.1111/j.1365-2796.2010.02236.x [DOI] [PubMed] [Google Scholar]
  42. Wahlin S., Stal P., Adam R., Karam V., Porte R., Seehofer D., et al. (2011a). Liver transplantation for erythropoietic protoporphyria in Europe. Transplant. Soc. 17 (9), 1021–1026. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver. 10.1002/lt.22341 [DOI] [PubMed] [Google Scholar]
  43. Wensink D., Coenen S., Wilson J. H. P., Wagenmakers M. A. E. M., Langendonk J. G. (2022). Liver involvement in patients with erythropoietic protoporphyria. Dig. liver Dis. official J. Italian Soc. Gastroenterology Italian Assoc. Study Liver 54 (4), 515–520. 10.1016/j.dld.2021.08.007 [DOI] [PubMed] [Google Scholar]
  44. Went L. N., Klasen E. C. (1984). Genetic aspects of erythropoietic protoporphyria. Ann. Hum. Genet. 48 (2), 105–117. 10.1111/j.1469-1809.1984.tb01006.x [DOI] [PubMed] [Google Scholar]
  45. Whatley S. D., Ducamp S., Gouya L., Grandchamp B., Beaumont C., Badminton M. N., et al. (2008). C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am. J. Hum. Genet. 83 (3), 408–414. 10.1016/j.ajhg.2008.08.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Yien Y. Y., Ducamp S., van der Vorm L. N., Kardon J. R., Manceau H., Kannengiesser C., et al. (2017). Mutation in human CLPX elevates levels of δ-aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. Proc. Natl. Acad. Sci. 114 (38), E8045–E8052. 10.1073/pnas.1700632114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Yuen H. W., Becker W. (2023). “Iron toxicity,” in StatPearls (Bethesda, MD: StatPearls Publishing. National Library of Medicin; ). [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

DataSheet1.PDF (203.2KB, PDF)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Articles from Frontiers in Molecular Biosciences are provided here courtesy of Frontiers Media SA

RESOURCES